<DOC>
	<DOCNO>NCT00972244</DOCNO>
	<brief_summary>The purpose study obtain information efficacy safety dapagliflozin Japanese patient Type 2 Diabetes . This do comparing effect dapagliflozin placebo give oral dos .</brief_summary>
	<brief_title>Trial Evaluate Efficacy Safety Dapagliflozin Japanese Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Japanese Subjects type 2 diabetes mellitus . Strictly/relatively treatment naïve Subjects HbA1c ≥ 7.0 % ≤ 10 % , Subjects treat single two ( less half approve maximal dose ) oral antihyperglycaemic agent HbA1c ≤ 8 % . Provision inform consent . Having clinically relevant medical history concurrent disease cardiovascular disease , renal disease , retinopathy , hepatic disease haematological disease . The investigator ( ) judge Subject participate study accord screen test medical history .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Japanese</keyword>
	<keyword>phase 2</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>dapagliflozin</keyword>
</DOC>